病毒性肝炎研究
钟劲,研究员,博士生导师。1994年获四川大学学士学位;1997年获北京大学硕士学位;2003年获美国德克萨斯大学博士学位,随后到美国Scripps研究所做博士后。2007年受聘中国科学院上海巴斯德研究所研究员。现担任上海巴斯德研究所病毒性肝炎研究组研究组长,博士生导师,上海科技大学特聘教授。
上海微生物学会病毒学专业委员会主任
上海市医学会医学病毒学分会副主任
Section Editor, hLife
Associate Editor, Journal of Medical Virology
Associate Editor, Virology Journal
Editorial Board Member, Antiviral Research
Editorial Board Member, Emerging Microbes and Infections
Editorial Board Member, Virologica Sinica
编委,临床肝胆病杂志
编委,中国病毒病杂志
部分通讯作者论文
1. Leumi, S., Guo, M., Lu, J., Wang, Z., Gan, T., Han, L., Ngari, J., Tong, Y., Xiang. X., Xie, Q., Wang, L., Zhong, J. (2022) Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. Antiviral Research, 197, 105224.
2. Yu, T. *, Yang, Q. *, Tian, F. *, Chang, H., Hu, Z., Yu, B., Han, L., Xing, QY., Jiu, Y., He, Y. Zhong, J. (2021) Glycometabolism regulates hepatitis C virus release. PLOS Pathogens. 17(7):e1009746. doi.org/10.1371/journal.ppat.1009746
3. Leumi, S., El Kassas, M., Zhong, J. (2021) Hepatitis C virus genotype 4: A poorly characterized endemic genotype. J. Med. Virol. 93(11):6079-6088. doi: 10.1002/jmv.27165.
4. Gan, T.*, Zhou, D. *, Huang, Y. *, Xiao, S., Ma, Z., Hu, X., Tong, Y., Yan, H. and Zhong, J. (2021) Development of a new reverse genetics system for Ebola virus. mSphere. 6, e00235-21. doi: 10.1128/mSphere.00235-21. (*contributed equally)
5. He, Z.*, Ye, S. *, Xing, Y., Jiu, Y. and Zhong, J. (2021) UNC93B1 curbs cytosolic DNA signaling by promoting STING degradation. European Journal of Immunology. 51(7):1672-1685. doi: 10.1002/eji.202048901. (*contributed equally)
6. Tong, Y.*, Shi, G. *, Hu, G., Hu, X., Han, L., Xie, X., Xu, Y., Zhang, R., Sun, J. and Zhong, J. (2021) Photo-catalyzed TiO2 inactivates pathogenic viruses by attacking viral genome. Chemical Engineering Journal, 414, 1287. doi: 10.1016/j.cej.2021.128788. (*contributed equally).
7. Liang, Y. *, Zhang, G. *, Li, Q. *, Han, L., Hu, X., Guo, Y., Tao, W., Zhao, X., Guo, M., Gan, T., Tong, Y., Xu, Y., Zhou, Z., Ding, Q., Wei, W. and Zhong, J. (2021) TRIM26 is a critical host factor for HCV replication and contributes to host tropism. Science Advances, 7, eabd9732. doi: 10.1126/sciadv.abd9732. (*contributed equally)
8. Tong, Y., Li, Q., Li, R., Xu, Y., Pan, Y., Niu, J., *Zhong, J., (2020) A novel approach to display structural proteins of HCV quasispecies in patients reveals a key role of E2 HVR1 in viral evolution. J. Virology, 94(17):e00622-20. doi: 10.1128/JVI.00622-20.
9. Guo, M., Ye, L., Yu, T., Han, L., Li, Q., Lou, P., Gan, T., Jin, X., Xiao, H., Meng, G., *Zhong, J., Xu, Y. (2020) IL-1β enhances anti-viral effect of IFN-α on HCV replication by negatively modulating ERK2 activation. ACS Infect Dis. 10;6(7):1708-1718. doi: 10.1021/acsinfecdis.9b00506. (*co-corresponding author)
10. Yi, C., Xia, J., He, L., Ling, Z., Wang, X., Yan, Y., Wang, J., Zhao, X., Fan, W., Sun, X., Zhang, R., Ye, S., Zhang, R., Xu, Y., Ma, L., Zhang, Y., Zhou, H., Huang, Z., Niu, J., Long, G., Lu, J., *Zhong, J., Sun, B. (2020) Junctional and somatic hypermutation-induced CX4C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibody. Cell Mol Immunol. doi: 10.1038/s41423-020-0403-1. (*co-corresponding author)
11. Yang, J., Xu, Y., Yan, Y., Li, W., Zhao, L., Dai, Q., Li, Y., Li, S., *Zhong, J., Cao, R., Zhong, W. (2020) Small Molecule Inhibitor of ATPase Activity of HSP70 as a Broad-Spectrum Inhibitor against Flavivirus Infections. ACS Infect Dis. 6(5):832-843. doi: 10.1021/acsinfecdis.9b00376. (*co-corresponding author).
12. Guo, M., Lu, J., Gan, T., Xiang. X., Xu, Y., Xie, Q. and Zhong, J. (2019) Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. Antiviral Research, 171, 104612. doi: 10.1016/j.antiviral.2019.104612.
13. *Yan, Y., *Wang, X., Lou, P., Hu, Z., Qu, P., Li, D., Li, Q., Xu, Y., Niu, J., He, Y., #Zhong, J., Huang, Z. (2020) A nanoparticle-based HCV vaccine with enhanced potency. J. Infectious Diseases, 221(8):1304-1314. doi: 10.1093/infdis/jiz228. (*The first two authors contributed equally; # co-corresponding author).
14. Zhao, Y., Cao, X., Guo, M., Wang, X., Yu, T., Ye. L., Han, L., Hei, L., Tao. W., Tong Y., Xu, Y. and Zhong, J. (2018) Neuralized E3 Ubiquitin Protein Ligase 3 is an inducible antiviral effector to inhibit HCV assembly by targeting viral E1 glycoprotein. J. Virology, 92(21). pii: e01123-18. doi: 10.1128/JVI.01123-18. JVI spotlight.
15. Tong, Y., Lavillette, D., Li, Q. and Zhong, J. (2018) Role of hepatitis c virus envelope glycoprotein E1 in virus entry and assembly. Front. Immunol. 9:1411. doi: 10.3389/fimmu.2018.01411
16. Liang, Y., Cao, X., Ding, Q., Zhao, Y., He, Z., Zhong, J. (2018) Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway. PLOS Pathogens. 14(5):e1007075. doi: 10.1371/journal.ppat.1007075.
17. Li, Q., Tong Y., Xu, Y., Niu, J., Zhong, J. (2018) Genetic Analysis of Serum-derived Defective Hepatitis C Virus Genomes Revealed Novel Viral Cis-Elements for Virus Replication and Assembly. J. Virology, 92(7). pii: e02182-17. doi: 10.1128/JVI.02182-17.
18. *Wang, X., *Yan, Y., Gan, T., Yang, X., Li, D., Zhou, D., Sun, Q., Huang, Z., Zhong, J. (2019) A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut, 68(1):140-149. doi: 10.1136/gutjnl-2017-314870. Epub 2017 Nov 27 (*The first two authors contributed equally).
19. *Tao, W., *Gan T., Guo, M., Xu, Y., Zhong, J. (2017) Novel Stable Ebola Virus Minigenome Replicon Reveals Remarkable Stability of the Viral Genome. J. Virology, 91: 22 e01316-17 (*The first two authors contributed equally). doi: 10.1128/JVI.01316-17. JVI spotlight.
20. Li, D., Wang, X., von Schaewen, M., Tao, W., Zhang, Y., Heller, B., Hrebikova, G., Deng, Q., Sun, Q., #Ploss, A., #Zhong, J., #Huang, Z. (2017) Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates. J. Infectious Diseases, 215(12):1824-1831 (#corresponding author).
21. *Cao, R., *Xu, Y., Zhang, T., Yang, J., Yuan, Y., Hao, P., Shi, Y., #Zhong, J., #Zhong, W. (2017) Pediatric drug nitazoxanide: a potential choice for control of Zika. Open Forum Infectious Diseases, 4(1):ofx009 (*The first two authors contributed equally; #corresponding author).
22. Tong, Y., Chi, X., Yang, W., Zhong, J. (2017) Functional analysis of HCV envelope protein E1 using a trans-complementation system reveals a dual role of a putative fusion peptide of E1 in both HCV entry and morphogenesis. J. Virology, 91:7 16 e02468-16
23. Hei, L. and Zhong, J. (2017) LGP2 plays an essential role in HCV infection-induced interferon responses. Hepatology, 65(5):1478-1491.
24. *Yan, Y., *He, Y., Boson, B., Wang, X., Cosset, F.L., Zhong, J. (2017) A point mutation in the N-terminal amphiphathic helix α0 in NS3 promotes HCV assembly by altering core localization to ER and facilitating virus budding. J. Virology, 91(6). pii: e02399-16 (*The first two authors contributed equally).
25. *Tao, W., *Gan T., Lu, J., Zhong, J. (2017) A Profiling Study of a Newly Developed HCVcc Strain PR63cc’s Sensitivity to Direct-acting Antivirals. Antiviral Research, 139:18-24 (*The first two authors contributed equally).
26. Li, D., von Schaewen, M., Wang, X., Tao, W., Zhang, Y., Li, L., Heller, B., Hrebikova, G., Deng, Q., #Ploss, A., #Zhong, J., #Huang, Z. (2016) Altered glycosylation patterns increase immunogenicity of a subunit HCV vaccine inducing neutralizing antibodies which confer protection in mice. J. Virology, 90:10486-10498 (#corresponding author).
27. Xu, Y., and Zhong, J. (2016) Innate immunity against hepatitis C virus. Current Opinion in Immunology. 42:98-104.
28. Li, D., Huang, Z. and Zhong, J. (2015) Hepatitis C virus vaccine development: old challenges and new opportunities. National Science Review, 2 (3): 285.
29. Xiang, Y., Tang, J., Tao, W., Cao, X., Song, B. and Zhong, J. (2015) Identification of cholesterol-25-hydroxylase as a novel host restriction factor as a part of primary innate immune responses against hepatitis C virus infection. J. Virology, 89:6805–6816.
30. *Cao, X., *Ding, Q., Lu J., Tao, W., Huang, B., Zhao, Y., Niu, J., Liu, Y.J. and Zhong, J. (2015) MDA5 Plays a Critical Role in Interferon Response during Hepatitis C Virus Infection. J. Hepatology. 62:771–778 (*The first two authors contributed equally) .
31. *Chen, W., *Xu, Y., Li, H., Tao, W., Xiang, Y., Huang, B., Niu, J., #Zhong, J. and #Meng, G. (2014) HCV Genomic RNA Activates the NLRP3 Inflammasome in Human Myeloid Cells. PLoS One, 9(1):e84953 (*The first two authors contributed equally; #corresponding author).
32. Lu, J., Xiang, Y., Tao, W., Li, Q., Wang, N., Gao, Y., Xiang, X., Xie, Q., and Zhong, J. (2014) A novel strategy to develop robust infectious hepatitis C virus cell culture system directly from a clinical isolate. J. Virology, 88, 1484-1491.
33. *Xu, Y., *Li, H., Chen, W., Yao, X., Xing, Y., Wang, X., #Zhong, J. and #Meng, G. (2013) Mycoplasma hyorhinis Activates the NLRP3 Inflammasome and Promotes Migration and Invasion of Gastric Cancer Cells. PLoS One, 8(11): e77955 (*The first two authors contributed equally; #corresponding author).
34. *Qi, Y., *Xiang, Y., Wang, J., Qi, Y., Li, J., #Niu, J., and #Zhong, J. (2013) Inhibition of Hepatitis C Virus Infection by Polyoxometalates. Antiviral Research, 100(2), 392-398 (*The first two authors contributed equally; #corresponding author).
35. Lu, J., Tao, W., Li, R., Xiang, Y., Zhang, N., Xiang, X., #Xie, Q., and #Zhong, J. (2013) Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates. Virology, 443(1), 80-88 (#corresponding author).
36. *Ding, Q., *Cao, X., Lu J., Huang, B., Liu, Y.J., Kato, N., Shu, H., and Zhong, J. (2013) Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J. Hepatology. 59(1):52-58 (*The first two authors contributed equally).
37. Kang, X., Chen, X., He, Y., Guo, D., Guo, L., #Zhong, J., #Shu, H. (2013) DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus. Virology, 435(2), 385-394 (#corresponding author).
38. Ding, Q., Huang, B., Lu, J., Liu, Y.J., and Zhong, J. (2012) Hepatitis C virus NS3/4A protease blocks IL-28 production. European J. Immunology, 42, 2374-82.
39. He, Y., Weng, L., Li, R., Li, L., Toyoda, T., and Zhong, J. (2012) The N-terminal helix a0 of hepatitis C virus NS3 protein dictates the subcellular localization and stability of NS3/NS4A complex. Virology, 422, 214-223.
40. Li, R., Qin, Y., He, Y., Tao, W., Zhang, N., Tsai, C., Zhou, P., Zhong, J. (2011) Production of hepatitis C virus lacking the envelope-encoding genes for single-cycle infection by providing homologous envelope proteins or vesicular stomatitis virus glycoproteins in trans. J.Virology,85, 2138-2147.
41. Xiang, X., Lu, J., Dong, Z., Zhou, H., Tao, W., Guo, Q., Zhou, X., #Xie, Q., #Zhong, J. (2011) Viral Sequence Evolution in Chinese Genotype 1b Chronic Hepatitis C Patients Experiencing Unsuccessful Interferon Treatment. Infect. Genet. Evol., 11, 382-390 (#corresponding author).
42. Tao, W., Xu, C., Ding, Q., Li, R., Xiang, Y., Chung, J., and Zhong, J. (2009) A Single Point Mutation in E2 Enhances Hepatitis C Virus Infectivity and Alters Lipoprotein Association of Viral Particles. Virology, 395, 67–76.
2022年
阐明了HCV针对索非布韦的耐药机制
尽管已经在 HCV直接抗病毒药物 (DAA) 的研发成功,但由于目前缺乏有效的预防性疫苗以及病毒亚基因组中耐药性突变位点的出现,彻底消灭这种病毒性流行病仍然任重而道远。索非布韦(Sofosbuvir, SOF) 是一种靶向病毒 RNA 依赖性 RNA 聚合酶 (RdRp) NS5B 的核苷酸类似物,是许多治疗方案中的关键组分。已有报道NS5B-S282T是SOF 的主要耐药相关替换性突变 (RAS),但该RAS同时会严重损害病毒的适应能力,因此这种突变在临床分离株中很少见。基因1型(GT1) 是世界范围内的一种主要的 HCV 基因型,在本项研究中我们使用了来自HCV GT1b 患者 PR52 血清中的准种群体来选择复制效率最佳的克隆,构建了复制子细胞(PR52D4)。为了获得 SOF 抗性复制子细胞,PR52D4 复制子细胞在SOF 和G418 处理的情况下培养 12 周。筛选出的细胞比亲本细胞对 SOF 表现出更强的抵抗力,同时保持了良好的病毒复制水平。测序结果表明,复制子细胞各有两个的 突变,PR52D4复制子细胞NS5B上获得 K74R 和 S282T突变。反向遗传学分析表明,虽然具有任意单一突变的 PR52D4 无法复制,但同时具有K74R+S282T 双突变的 PR52D4不但能够有效复制,还具有SOF 抗性。 重要的是,K74R 突变还可以挽救另一个 GT1b 复制子 Con1 中S282T引起的复制缺陷,在GT2a复制子JFH1中也是如此。 结构模型分析表明,K74R 可能与 HCV 聚合酶活性位点中的 Y296 相互作用来帮助稳定S282T。我们的研究结果对临床上选择合适的DAA治疗方案具有一定的指导意义。(Leumi, et al., Antiviral Research, 2022)
2021年
基于人肝癌细胞系Huh7建立的HCV细胞培养模型为研究HCV感染周期提供了帮助。然而,由于代谢重编程的存在,肿瘤细胞即使在有氧条件下,仍然使用糖酵解作为主要的能量来源,而不像正常体细胞那样主要使用氧化磷酸化来供能,这种现象叫做“瓦博格效应”。将培养基中的糖源从葡萄糖换为半乳糖,可以逆转体外培养肿瘤细胞的瓦博格效应。
我们发现将Huh7细胞培养在以半乳糖作为糖源的培养基中,可以显著抑制HCV病毒粒子的释放,大量的病毒粒子聚集在细胞内的多泡体内而无法释放到细胞外。阻断多泡体与溶酶体的融合或使用促炎细胞因子处理可以在一定程度上恢复半乳糖培养条件下HCV的释放。MAPK-p38通路在宿主细胞糖代谢对HCV释放的调控中发挥了重要的作用。
我们研究还发现HCV在细胞与细胞间直接传播并不受宿主细胞糖代谢的影响。科研人员提出猜想,HCV在病人体内可能主要以细胞与细胞间直接传播为主,而不是通过释放到细胞外和血液中以感染邻近的细胞,并以此逃逸抗体的中和作用和宿主的免疫监视,这可能是HCV建立慢性持续感染的重要机制。为深入理解细胞糖代谢与HCV释放的相互关系以及HCV自然感染过程提出了新的见解。(Yu, et al., PLOS Pathogens , 2021)
UNC93B1(unc-93 homolog B1)是内体Toll样受体(TLRs)的运输伴侣,在TLR介导的天然免疫信号转导中起重要作用。本研究在小鼠和人细胞系中研究了UNC93B1在胞浆DNA诱导cGAS-STING信号通路中的作用。我们发现,虽然UNC93B1缺失减弱了双链RNA诱导的TLR3的信号转导,但增强了对胞浆DNA刺激和DNA病毒感染的天然免疫应答。机制研究表明,UNC93B1通过提高静息和胞浆DNA刺激条件下STING蛋白水平,而不是调控cGAS-STING-TBK1信号通路的其他分子,增强了DNA刺激的天然免疫应答。UNC93B1直接与STING相互结合并共同转运,这种相互作用的破坏导致STING蛋白的累积。本研究发现了UNC93B1负调控STING介导的信号反应,揭示了UNC93B1的新功能。(He, et al., European Journal of Immunology, 2021)
2020年
2019年
我们之前的研究表明,发现经过修饰的E2重组蛋白(sE2)免疫小鼠和恒河猴后可以有效诱导中和抗体及T细胞应答。在本项工作中,我们设计了一种融合蛋白(sE2-铁蛋白),该蛋白在果蝇S2细胞内能自发组装成纳米颗粒。该纳米颗粒的表面展示了sE2,其sE2部分不仅具有接近自然的构象,而且相较于单独表达的sE2蛋白,融合蛋白与受体分子、中和抗体、丙肝患者血清中的HCV特异性多克隆抗体的结合力更好。小鼠免疫研究表明,sE2-铁蛋白纳米颗粒抗原比sE2抗原更加有效地诱导出广谱中和抗体。综上所述,以sE2-铁蛋白自组装的纳米颗粒候选疫苗,在免疫原性上优于以前开发的sE2疫苗,为HCV疫苗研发提供了新的可能性(Yan, Wang, et al., The Journal of Infectious Diseases , 2019)。
2022 上海市优秀学术带头人
2017 中科院分子病毒与免疫重点实验室“杰出成就奖”
2016 中科院“优秀研究生指导教师”奖
2014 中科院“优秀研究生指导教师”奖
2013 国务院政府特殊津贴专家
2012 中科院“朱李月华”优秀教师奖
2009 中科院百人计划择优项目支持
本实验室研究重要RNA病毒病原体的分子病毒学、细胞生物学、固有免疫应答以及抗病毒疫苗和药物的研发,主要研究对象包括丙型肝炎病毒(HCV)、埃博拉病毒(EBOV)、寨卡病毒(ZIKV)等。HCV能导致急性和慢性肝炎以及肝癌。近年来慢性丙肝的治疗研究有了很大的进展,但是由于缺乏丙肝疫苗,丙肝问题仍然威胁着人类的健康。HCV作为一个正链RNA模式病毒,遗传多样性高。其病毒颗粒与宿主来源的脂蛋白复合物高度关联,在其生命周期和宿主相互作用上具有鲜明的特点。EBOV和ZIKV是新发突发致病性RNA病毒,近年来多次引起全球或区域流行,给世界公共卫生健康造成较大的威胁。我们在分子及细胞水平上研究这些RNA病毒感染的生物学机制,阐明病毒学、免疫学和细胞生物学中重要的科学问题,找到更好的途径和手段来预防和治疗病毒感染。
实验室成员(Lab member)
副研究员:童一民 博士
研究助理:马子越
科研秘书:夏佳梦
国科大博士研究生:邢一帆、叶思超、田芳玲、胡逍悠、李林灿、吴天昊、JACKLINE WANGU NGARI
国科大硕士研究生:白旭
上科大硕士研究生:刘超仑、常钰
毕业研究生(Graduate student)
已毕业博士研究生:陶万银、何莹、李瑞、丁强、卢捷、曹学智、向禹、黑蕾、于涛、颜雨、李庆超、王雪松、赵亚楠、何振亮、郭明哲、甘天喻、梁轶莎、韩林、娄佩兰、STEVE LEUMI YATCHOUKEU、杨乾坤
已毕业硕士研究生:叶丽清、谢磊、田芳玲、胡逍悠、马子越
已毕业联合培养博士研究生:项晓刚、李大鹏
招生信息(admission information)
欢迎优秀的博士生毕业生来课题组做博士后。
欢迎优秀学生加入本团队攻读硕士和博士研究生。
欢迎大学二年级(含)以上同学进入实验室参与有关科研学术工作,或联系毕业设计等。